Wyeth’s Pristiq (corr.)
Executive Summary
Wyeth's antidepressant Pristiq (desvenlafaxine) is a racemic mixture and the succinate salt of a metabolite of venlafaxine (Wyeth's Effexor), not a single enantiomer as stated in the "The Pink Sheet" Jan. 15 (1"The Pink Sheet" Jan. 15, 2007, p. 26). FDA is considering the Effexor XR follow-on to be a new molecular entity, Wyeth says...
You may also be interested in...
2007 NME Prospects Plentiful For Wyeth, Novartis – Other Firms Fall Short
The year 2007 holds the potential to fatten Wyeth's new drug lineup: after a lean 2006, when no Wyeth new molecular entities were approved, the company leads the industry in potential NME approvals for the coming year
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.